Divisions of Cardiovascular Diseases (D.B.S., P.J.P., M.S., D.R.H., B.J.G., C.S.R., R.D.S., R.G.) and Biomedical Statistics and Informatics (R.J.L.), Mayo Clinic, Rochester, MN; and Division of Cardiovascular Diseases (I.D.M.), Mayo Clinic, Jacksonville, FL.
Circulation. 2014 Mar 25;129(12):1286-94. doi: 10.1161/CIRCULATIONAHA.113.006518. Epub 2014 Feb 10.
The impact of changing demographics on causes of long-term death after percutaneous coronary intervention (PCI) remains incompletely defined.
We evaluated trends in cause-specific long-term mortality after index PCI performed at a single center from 1991 to 2008. Deaths were ascertained by scheduled prospective surveillance. Cause was determined via telephone interviews, medical records, autopsy reports, and death certificates. Competing-risks analysis of cause-specific mortality was performed using 3 time periods of PCI (1991-1996, 1997-2002, and 2003-2008). Final follow-up was December 31, 2012. A total of 19 077 patients survived index PCI hospitalization, of whom 6988 subsequently died (37%, 4.48 per 100 person-years). Cause was determined in 6857 (98.1%). Across 3 time periods, there was a 33% decline in cardiac deaths at 5 years after PCI (incidence: 9.8%, 7.4%, and 6.6%) but a 57% increase in noncardiac deaths (7.1%, 8.5%, and 11.2%). Only 36.8% of deaths in the recent era were cardiac. Similar trends were observed regardless of age, extent of coronary disease, or PCI indication. After adjustment for baseline variables, there was a 50% temporal decline in cardiac mortality but no change in noncardiac mortality. The decline in cardiac mortality was driven by fewer deaths from myocardial infarction/sudden death (P<0.001) but not heart failure (P=0.85). The increase in noncardiac mortality was primarily attributable to cancer and chronic diseases (P<0.001).
This study found a marked temporal switch from predominantly cardiac to predominantly noncardiac causes of death after PCI over 2 decades. The decline in cardiac mortality was independent of changes in baseline clinical characteristics. These findings have implications for patient care and clinical trial design.
人口结构变化对经皮冠状动脉介入治疗(PCI)后长期死亡原因的影响尚不完全明确。
我们评估了 1991 年至 2008 年在一家中心进行的经皮冠状动脉介入治疗后特定原因的长期死亡率趋势。通过定期前瞻性监测确定死亡。死因通过电话访谈、病历、尸检报告和死亡证明确定。使用经皮冠状动脉介入治疗的 3 个时间段(1991-1996 年、1997-2002 年和 2003-2008 年)进行特定原因死亡率的竞争风险分析。最终随访日期为 2012 年 12 月 31 日。共有 19077 例患者在经皮冠状动脉介入治疗住院期间存活,其中 6988 例随后死亡(37%,4.48/100 人年)。在 6857 例(98.1%)中确定了死因。在 3 个时间段内,PCI 后 5 年的心脏死亡下降了 33%(发生率:9.8%、7.4%和 6.6%),而非心脏死亡增加了 57%(7.1%、8.5%和 11.2%)。最近时代只有 36.8%的死亡是心脏原因。无论年龄、冠状动脉疾病程度或 PCI 适应证如何,都观察到类似的趋势。在调整基线变量后,心脏死亡率下降了 50%,而非心脏死亡率没有变化。心脏死亡率的下降主要归因于心肌梗死/猝死死亡减少(P<0.001),而心力衰竭死亡没有变化(P=0.85)。非心脏死亡率的增加主要归因于癌症和慢性疾病(P<0.001)。
这项研究发现,在 20 多年的时间里,经皮冠状动脉介入治疗后死亡原因从以心脏为主明显转变为以非心脏为主。心脏死亡率的下降独立于基线临床特征的变化。这些发现对患者护理和临床试验设计具有重要意义。